Publications by authors named "Philippe Moingeon"

Claim this Profile
M
Multi-omic analysis identifies biological processes underlying progressive interstitial lung disease in systemic sclerosis.
Selena Bouffette, Perrine Soret, Alice Cole, Emmanuel Nony, Pierre Barbier Saint Hilaire, Philippe Moingeon

FEBS J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).
Simon J Bowman, Raphaele Seror, Raphael Porcher, Suzanne Arends, Liseth de Wolff, Philippe Moingeon

Ann Rheum Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Therapeutic Targets for Amyotrophic Lateral Sclerosis Through Modeling of Multi-Omics Data.
François Xavier Blaudin de Thé, Cornelius J H M Klemann, Ward De Witte, Joanna Widomska, Philippe Delagrange, Philippe Moingeon

Int J Mol Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic markers for knee osteoarthritis presence are not associated with disease progression - data from the IMI-APPROACH cohort.
Mieke L M Bentvelzen, Paco M J Welsing, Philippe Moingeon, Simon C Mastbergen, Margreet Kloppenburg

PLoS One· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual patients inspired by multiomics predict the efficacy of an anti-IFNα mAb in cutaneous lupus.
Vincent Hurez, Glenn Gauderat, Perrine Soret, Renee Myers, Krishnakant Dasika, Philippe Moingeon

iScience· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome.
Emiko Desvaux, Patrice Hemon, Perrine Soret, Christelle Le Dantec, Loukas Chatzis, Philippe Moingeon

J Autoimmun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing the power of AI-based models to accelerate drug discovery against immune diseases.
Philippe Moingeon

Expert Rev Clin Immunol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease.
Cheïma Boudjeniba, Perrine Soret, Diana Trutschel, Antoine Hamon, Valentin Baloche, Philippe Moingeon

Clin Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Artificial intelligence-driven drug development against autoimmune diseases].
Philippe Moingeon

Med Sci (Paris)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The revolution of AI in drug development].
Philippe Moingeon, Christiane Garbay, Muriel Dahan, Irène Fermont, Ali Benmakhlouf

Med Sci (Paris)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transforming drug discovery with a high-throughput AI-powered platform: A 5-year experience with Patrimony.
François-Xavier Blaudin de Thé, Claire Baudier, Renan Andrade Pereira, Céline Lefebvre, Philippe Moingeon

Drug Discov Today· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials.
Philippe Moingeon, Marylore Chenel, Cécile Rousseau, Emmanuelle Voisin, Mickael Guedj

Drug Discov Today· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence-driven drug development against autoimmune diseases.
Philippe Moingeon

Trends Pharmacol Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises.
Laurence Laigle, Loubna Chadli, Philippe Moingeon

Expert Rev Clin Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industrializing AI-powered drug discovery: lessons learned from the computing platform.
Mickaël Guedj, Jack Swindle, Antoine Hamon, Sandra Hubert, Emiko Desvaux, Philippe Moingeon

Expert Opin Drug Discov· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Systemic lupus erythematosus: A new indication for CAR-T cell therapies?].
Emiko Desvaux, Philippe Moingeon, Antoine Bril, Hélène Trebeden-Negre

Med Sci (Paris)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Sjögren's syndrome: Towards precision medicine].
Laurence Laigle, Christelle Le Dantec, Perrine Soret, Emiko Desvaux, Sandra Hubert, Philippe Moingeon

Med Sci (Paris)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine.
Philippe Moingeon, Mélaine Kuenemann, Mickaël Guedj

Drug Discov Today· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based computational precision medicine to develop combination therapies for autoimmune diseases.
Emiko Desvaux, Audrey Aussy, Sandra Hubert, Florence Keime-Guibert, Alexia Blesius, Philippe Moingeon

Expert Rev Clin Immunol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomics in support of immunotherapy: contribution to model-based precision medicine.
Emmanuel Nony, Philippe Moingeon

Expert Rev Proteomics· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applications of transcriptomics in support of drug development for osteoarthritis.
Hélène Kaplon, Yufei Luo, Frédéric De Ceuninck, Agnès Lalande, Sophie Courtade-Gaiani, Philippe Moingeon

Osteoarthr Cartil Open· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases.
Frédéric De Ceuninck, Fanny Duguet, Audrey Aussy, Laurence Laigle, Philippe Moingeon

Drug Discov Today· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A deep learning method for predicting knee osteoarthritis radiographic progression from MRI.
Jean-Baptiste Schiratti, Rémy Dubois, Paul Herent, David Cahané, Jocelyn Dachary, Philippe Moingeon

Arthritis Res Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19.
Emiko Desvaux, Antoine Hamon, Sandra Hubert, Cheïma Boudjeniba, Bastien Chassagnol, Philippe Moingeon

PLoS One· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome.
Perrine Soret, Christelle Le Dantec, Emiko Desvaux, Nathan Foulquier, Bastien Chassagnol, Philippe Moingeon

Nat Commun· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis